The use of omalizumab in asthma.

Primary Care Respiratory Journal : Journal of the General Practice Airways Group
David Price

Abstract

Asthma causes a substantial burden of morbidity and mortality, affecting 300 million people worldwide - a figure predicted to increase to 400 million by 2025. Despite the availability of a variety of treatment options and detailed treatment guidelines, many patients with asthma, and in particular those with severe persistent asthma, remain inadequately controlled. Approximately 50-80% of severe asthma has an allergic component, with immunoglobulin E (IgE) playing a role in the underlying allergic inflammatory cascade. Omalizumab is a humanised monoclonal anti-IgE antibody that targets IgE and partially inhibits the inflammatory cascade. Clinical trials have demonstrated that omalizumab added to standard asthma therapy reduces exacerbations and emergency visits with concomitant improvements in asthma control and quality of life in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. Add-on omalizumab is indicated for the treatment of patients with inadequately controlled moderate-to-severe (US label) and severe (EU label) persistent allergic asthma despite treatment with high-dose inhaled corticosteroids (and in the EU, high-dose inhaled corticosteroids plus a long-acting beta2-agonist). Within ...Continue Reading

Citations

Jul 28, 2011·Journal of Asthma and Allergy·Girolamo PelaiaAlessandro Vatrella
Dec 27, 2012·Allergologia et immunopathologia·J AncocheaJ Casafont
Dec 21, 2012·Allergologia et immunopathologia·T VieiraM da Graça Castel-Branco
Mar 19, 2013·Chest·Lamiae Grimaldi-BensoudaUNKNOWN Pharmacoepidemiology of Asthma and Xolair (PAX) Study Group
Dec 10, 2013·Respiratory Medicine·Roland BuhlGiorgio Walter Canonica
Oct 12, 2010·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Stephanie KornRoland Buhl
Jul 12, 2011·The Clinical Respiratory Journal·Christian SchumannClaus Kroegel
Mar 27, 2012·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·María Del Carmen VenneraUNKNOWN Spanish Registry
Apr 14, 2009·Respiratory Medicine·Stephen HolgatePablo Jimenez
Apr 18, 2013·The Journal of Allergy and Clinical Immunology·William BusseOral Alpan
Aug 14, 2012·Respiratory Medicine·Stephanie KornRoland Buhl
May 14, 2016·Pediatrics International : Official Journal of the Japan Pediatric Society·Hideki YoshikawaHiroshi Odajima
Nov 1, 2008·Expert Review of Clinical Immunology·Santiago Quirce, Joaquin Sastre
Jan 7, 2009·Therapeutic Advances in Respiratory Disease·Girolamo PelaiaRosario Maselli
Oct 29, 2017·Thorax·Maria Del Carmen VenneraUNKNOWN Spanish Omalizumab Registry
Nov 8, 2018·Therapeutic Advances in Respiratory Disease·Corrado PelaiaGirolamo Pelaia
Oct 3, 2009·Current Opinion in Pulmonary Medicine·David Gruenberg, William Busse
Sep 2, 2011·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·Nobuhiro AsaiNorihiro Kaneko
Jan 18, 2013·Journal of Immunoassay & Immunochemistry·Pavel StrohnerGunther Becher
Jul 13, 2021·Frontiers in Pharmacology·Mengli RenGuiqiong He

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.